CSIR in the news..

An aggregation of news on the web about CSIR and its laboratories

Archive for the ‘IIIM’ Category

IIIM Celebrates Foundation Day

SRINAGAR: 58th Foundation Day of CSIR–IIIM, Jammu was celebrated at the Indian Institute of Integrative Medicine (CSIR-IIIM) Jammu on 1st December 2015.

Prof Shannon B Olsson, a distinguished faculty member of National Centre for Biological Sciences (NCBS), Bangalore, was the chief guest of this function, a statement issued here this evening said.

On this occasion, the students from different colleges and schools in the city were taken on a guided visit to the various research divisions and medicinal fields of the institute. The Scientists and Technical staff have demonstrated their indoor and field research activities to the visitors…

Read more:http://www.kashmirlife.net/iiim-celebrates-foundation-day-90956/

Written by csirindia

December 2, 2015 at 12:32 pm

Posted in IIIM, Uncategorized

Director IIIM-CSIR highlights use of medicinal, aromatic plants

29 October 2015

JAMMU: “State of Jammu and Kashmir possesses immense potential for cultivation of medicinal and aromatic plants and rural prosperity can be restored via propagating these plants for sustainable rainfed agriculture”.
This was stated by  Dr Ram Vishwakarma, Director, Indian Institute of Integrative Medicine (formerly RRL) while delivering a brainstorming lecture at the second day of 4th  JK Agricultural Science Congress at Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu (SKUAST-Jammu)….

Source: http://www.dailyexcelsior.com/director-iiim-csir-highlights-use-of-medicinal-aromatic-plants/

Written by csirindia

October 30, 2015 at 9:07 am

Posted in IIIM

Count on ayurveda for low platelet count cure soon!

06 July 2012

BHOPAL: Using natural ayurveda remedies researchers may soon have a cure for low platelet count, according to Indian Institute of Integrative Medicine (IIIM) director Ram Vishwakarma. Researchers claim that by using some six key medicinal plants they can stop fall and bring back platelet count in 7-8 days to normal levels of over one lakh per cubic mm.

According to Vishwakarma, dossier for phase one trial of the drug is being prepared. If successful, the research would have be a huge help to stop fall in platelet count in viral diseases like dengue or during chemotherapy for cancer patients. Fall in platelet count becomes life threatening if the level slips to 25,000 unit. Until now the cure for increasing platelet immediately is more platelet transfusion…..

Read more: http://articles.timesofindia.indiatimes.com/2012-07-06/bhopal/32565027_1_medicinal-plants-platelet-ayurveda-drug

Written by csirindia

July 8, 2012 at 11:15 am

Posted in IIIM

Jammu institute develops breast cancer drug

17 January 2012

JAMMU:  The Indian Institute of Integrative Medicine (IIIM), Jammu, has developed a drug for the treatment of hypertension and breast cancer, an official said. The drug ‘Risorine’ is presently used by the medical fraternity for management of tuberculosis.

The director said the institution has “produced drugs with low toxicity for the treatment of hyper-tension and breast cancer.”

He said “Jammu and Kashmir is the only state in the world which produces basic drug element ‘texas beccata’ for management of cancers,” and claimed that the IIIM, Jammu has “one of the four highly technical laboratories in the country to handle microbes and conduct researches.”…..

Read more: http://www.deccanjournal.com/jammu-institute-develops-breast-cancer-drug/

Written by csirindia

January 21, 2012 at 10:38 am

Posted in IIIM

Focus more on drug discovery

23 September 2011

CHENNAI: Ram A Vishwakarma, director of the Indian Institute of Integrative Medicine of the Council of Scientific and Industrial Research, urged students to discover more drugs to solve various health issues.
Addressing students at the 14th convocation at Sri Ramachandra University, he said, “Five or six centuries ago, India was a world leader in medical therapies, concepts, equipment and surgeries. Today, however, we have lost our capacity to do so, as shown by the fact that not a single drug discovered and developed in India is in the global market….

Written by csirindia

September 23, 2011 at 10:41 pm

Posted in IIIM

US looks to India to strengthen co-operation in Ayurveda-Siddha-Unani herbal and botanical products of global standard

09 December 2010

BANGALORE: India’s rich bio-diversity in herbs has now attracted the US to look for possible collaboration in the area of integrative medicine.

In the last two years, the setting up of the Centre for Research in Indian Systems of Medicine (CRISM) by the Department of Ayush at the National Centre for Natural Products Research, University of Mississippi, USA has increased the co-operation in the field of development of Ayurveda-Siddha-Unani (ASU) herbal and botanical products of global standards.

The Centre is facilitating internationally important joint research for the scientific validation of Indian Systems of Medicine (ISM) including Ayurveda, Unani and Siddha and for creating greater awareness about these systems and their products in the US and other countries.

…..“We need to de-mystify the myths of ASU medicines. There is need to standardise the products and ensure a scientific acceptance of the system. These efforts would are required as US looks to India to strengthen co-operation in developing herbal and botanical products of global standard,” stated Dr Ram Vishwakarma, director, Indian Institute of Integrative Medicine.

Read more: http://www.pharmabiz.com/article/detnews.asp?articleid=58760&sectionid=

Written by csirindia

December 10, 2010 at 9:18 am

Posted in IIIM

From Oceans to Crops, and From Crops to IPO – Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the Ocean

leave a comment »

15 February 2010


Avesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation. Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well. Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.

Avesthagen has strengthened it’s Board of Directors with Dr. John Darbyshire, Operations Manager of the Beverages SBU at Nestle, Switzerland, Ms. Dominique Takizawa, Chief Financial Officer, Institute Merieux, and Dr. Chris Bowler, Professor, Molecular Marine Biology, Ecole Normale Superieure, Paris, France. They bring strategic, scientific direction to Avesthagen.

…..Finally, Avesthagen would like to share with the public the successful completion of the NIMTLI project. In 2003, Avesthagen Limited and its research partners-the National Institute of Oceanography (Goa), the Regional Research Laboratory (Jammu), and the Indian Institute of Chemical Technology (Hyderabad) had received funding from the Council of Scientific and Industrial Relations (CSIR) for their research proposal entitled: “Recombinant approach to produce alpha-linolenic acid and docosahexanoic acid (DHA) in sunflower and yeast”. This truly innovative project has been completed wherein Avesthagen has successfully cloned genes from microalgae for production of DHA and other useful omega-3 and omega-6 fatty acids. Patents have been filed for ALA, GLA, DGLA, ARA, and EPA, while the filing for DHA is in progress. A set of six genes is now being transformed into Brassica and Sunflower with the aim of overproducing DHA in these plants. The production of essential fatty acids such as DHA in plants will provide a commercially viable method for delivering these critical dietary components to the human population, while avoiding over-exploitation of natural resources and ecosystems…..Read complete news item……

Written by csirindia

February 18, 2010 at 4:56 pm

Posted in IICT, IIIM, NIO

PM to unveil new TB drug next week

leave a comment »

18 December 2009

By Saubhadro Chatterji & Joe C Mathew

Prime Minister Manmohan Singh will unveil a new anti-tuberculosis (TB) drug developed by Indian scientists next week.

The drug, known to be more effective than existing therapies, has been developed by Indian Institute of Integrative Medicine (IIIM), Jammu, after 12 years of research.

Ahmedabad-based Cadila Pharmaceuticals will market the medicine under the brand name “Risorine”.

According to Minister of State for Science and Technology Prithviraj Chavan, “Risorine will not be a stand-alone medicine. But if given along with Rifampicin—the key anti-TB drug—it would act as a catalyst to enhance the capacity of Rifampicin. In effect, the patient will require lesser doses of Rifampicin and the treatment would not take the usual long course.”

TB is a major public health problem in the country and India accounts for one-fifth of the global TB incident cases. According to World Health Organization figures, each year 2 million people in India develop TB, of which around 870,000 cases are infectious. It is estimated that TB accounts for around 330,000 death every year in the country.

According to officials, the decision to have PM unveil the drug signifies the huge public health problem the new drug attempts to address.

IIIM, a constituent laboratory of the Council of Scientific and Industrial Research (CSIR), developed Risorine as a combination of TB drugs Isoniazid and Rfampicin and piperine (extracts of black pepper). The scientists found that the combination enhances the bio-activity of both the TB drugs and therefore reduces the need for high doses……Read complete news item…..

Written by csirindia

December 18, 2009 at 4:44 pm

Posted in CSIR, IIIM

Cadila launches first indigenously prepared TB drug news

leave a comment »

31 October 2009

Cadila Pharmaceuticals Ltd today launched Risorine, the first indigenously prepared drug for the treatment of tuberculosis in India.

“The launch of Risorine, which is the world’s first boosted Rifampicin-containing fixed dose combination, promises to alter the way tuberculosis is treated at a global level,” said Cadila Pharma chairman Indravada Modi.

“Tuberculosis is a major cause of many illnesses and deaths worldwide. Globally, 9.2 million new cases and 1.7 million deaths from TB occurred in 2006. India is home to over 3.4 million tuberculosis patients, which is about one-fifth of the global figure, which makes it the most TB-prevalent country,” added Modi.

In a multi-centric trial conducted across the country in patients with radiologically confirmed diagnosis of pulmonary tuberculosis, more than 90 per cent of the patients treated with Risorine were found to have been cured of tuberculosis with comparatively lesser side effects and a better safety profile, Dr Naresh Patel, a consultant scientist of Cadila, added.

Risorine, he said, offers a cost-effective solution for treating the huge number of tuberculosis cases detected annually in the country, he added.

The drug is the result of a public-private partnership between the Indian Institute of Integrative Medicine, a Jammu-based unit of the Council of Scientific and Industrial Research, and Cadila Pharma.

Source: http://www.domain-b.com/industry/pharma/20091031_cadila.html

Written by csirindia

October 31, 2009 at 8:25 pm

Posted in IIIM

Drug course starts at NIPER

leave a comment »

20 October 2009

CHANDIGARH: A two-week intensive course on advanced analytical techniques: basic principals and application for quality assessment of drugs and pharmaceuticals for export organized by the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, kicked off on Monday.

The event was inaugurated by Dr Ram A Vishwakarma, director, Indian Institute of Integrative Medicine, Jammu. Speaking on the occasion, Vishwakarma said India was uniquely placed in the global pharmaceutical sector. Earlier, Prof P Rama Rao, director, NIPER, said the Indian pharmaceutical industry was ranked fourth in the world. Discussing the objective of the course, Prof AK Chakraborti, department of medical chemistry, said the workshop would provide an update on theoretical and practical aspects of various key issues related to pharmaceuticals. Around 22 resource persons will deliver lectures to 20 participants from various countries.

Source: http://timesofindia.indiatimes.com/city/chandigarh/Drug-course-starts-at-NIPER/articleshow/5140334.cms

Written by csirindia

October 20, 2009 at 6:30 am

Posted in IIIM